Ampicillin for Premature Babies

(OPTI-Amp Trial)

This trial explores whether preterm infants can safely receive a shorter course of the antibiotic ampicillin. Researchers aim to determine if stopping ampicillin between 24 to 36 hours after initiation is as effective as the standard 48-hour course. Preterm infants prescribed ampicillin for early signs of infection and admitted to Duke's Neonatal Intensive Care Unit may qualify. The trial involves collecting blood samples to check ampicillin levels and monitoring the infants' health for 30 days or until hospital discharge. As a Phase 1, Phase 2 trial, this research focuses on understanding the treatment's mechanism and measuring its effectiveness in a smaller group, offering a chance to contribute to significant medical advancements.

The trial does not specify if participants must stop other medications, but it does require stopping ampicillin earlier than usual. It's best to discuss your current medications with the trial team.

Research has shown that ampicillin is generally safe for premature babies. Studies indicate that administering two doses of ampicillin at 50 mg per kg effectively combats infections while minimizing side effects. Other research has found no major safety concerns with various antibiotic treatments for premature babies.

Most treatments for infections in premature babies involve a standard 48-hour course of empiric antibiotics like ampicillin. However, this new approach uses a short-course ampicillin regimen, lasting only 24 to 36 hours, adjusted for gestational age. Researchers are excited about this treatment because it could reduce the duration of antibiotic exposure in fragile infants, potentially minimizing the risk of antibiotic resistance and other side effects. By tailoring the treatment duration to the needs of premature infants, this approach may offer a safer and more efficient way to manage early infections.

This trial will evaluate the effectiveness of a short-course ampicillin regimen for premature babies. Studies have shown that shorter courses of ampicillin can effectively treat early-onset sepsis (EOS) in preterm infants. Research indicates that administering two doses of ampicillin at 50 mg/kg effectively kills bacteria while reducing the risk of side effects. Evidence suggests that many preterm infants retain enough of the drug in their system for at least 24 hours after the last dose. This continued presence means the drug remains effective even after stopping, supporting the idea that shorter antibiotic courses can be safe and effective. Overall, the data suggests that shorter courses could minimize the risk of side effects.¹²⁴⁶⁷